Although simultaneously inhibiting Bcl-2 and Mcl-1 results in synergistic induction of apoptosis in AML cells, the treatment also synergistically inhibited proliferation of normal PMNCs, indicating that toxicity may be a concern moving forward. The gene discussed is MCL1; the disease is acute myeloid leukemia.